- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Clinicaltrials.gov identifier NCT03925402
Recruitment Status Recruiting
First Posted April 24, 2019
Last update posted September 17, 2020
This study aims to assess whether ertapenem as an empiric treatment of third-generation-cephalosporin resistant Enterobacteriaceae (3GCRE) bacteremia is non-inferior to other carbapenems in term of 30-day mortality.
There are limited data of the efficacy of ertapenem as the empiric treatment of serious invasive infections, such as bloodstream infections (BSIs), that are due to ESBL-producing Enterobacteriaceae. Previous studies of ertapenem were done in small group of patients, in less invasive infection, as a definite 'step-down' therapy, or as compared to other non-carbapenem antibiotics.
Patients who received ertapenem as an empirical antibiotic
|: Other carbapenems
Patients who received carbapenems other than ertapenem as an empirical antibiotic
Other carbapenems injection
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, , Learn About Clinical Studies.-->
- Adults, either sex, ages 18 years or above
- Patients with 3GCRE bacteremia
- Patients admitted to any of the study sites
- Discontinuation of antibiotic due to transition to hospice care
- Polymicrobial bacteremia
- Empirical antibiotic after 24 hours of first evidence of bacteremia
Contact: Vasin Vasikasin, MD 027633338 firstname.lastname@example.org
Phramongkutklao College of Medicine and Hospital